Cito Biopharma: Subsidiary Receives Approval Notice for Market Application of Mometasone Furoate Chemical Raw Materials

Saito Biology announced that its holding subsidiary, Shandong Sui Rui Pharmaceutical Co., Ltd., recently received the "Approval Notice for the Marketing Application of Chemical Raw Materials for Pregabalin Mometasone" issued by the National Medical Products Administration. Pregabalin Mometasone has a strong anti-inflammatory effect and can be used for inhalation and local skin topical drugs, mainly used to treat asthma, eczema, neurodermatitis, atopic dermatitis, and skin itching. The company's chemical raw material Pregabalin Mometasone has obtained the "Approval Notice for the Marketing Application of Chemical Raw Materials", indicating that the raw material has met the relevant national drug evaluation technical standards. This approval will further enrich the company's product line and enhance the company's market competitiveness in the field of chemical raw materials.